Latest Safety News

Savannah Goldfields reports steady gold production at its Georgetown plant, with new feedstock from historic sites and a third-party toll treatment agreement supporting continuous operations.

HITIQ Limited and Sportscover have forged an exclusive partnership to embed PROTEQT™, a cutting-edge concussion management system, into Sportscover’s sports insurance policies, starting with Hockey Australia and set to expand further.

Lindian Resources has optimised its Kangankunde Rare Earths Project, increasing ore processing capacity by 25% and appointing Obsideo as the design and construction contractor for its processing plant. This upgrade significantly enhances the project's financial outlook while keeping capital costs within budget.

Gibb River Diamonds has begun trucking and processing operations at its Neta Gold Mine, securing 130,000 tonnes of ore for milling at two contracted facilities in Western Australia.

HITIQ Limited has successfully completed the initial tranche of a $900,000 placement, issuing over 40 million shares with attached options, while director participation awaits shareholder approval.

Entropy Neurodynamics has successfully completed dosing the first patient in its TRP-8803 clinical trial for Binge Eating Disorder, marking a key milestone with controlled psychedelic infusion and safety clearance. Top-line results are expected in early 2026.

Immutep Limited reports robust progress in its pivotal Phase III TACTI-004 trial for advanced non-small cell lung cancer, with over 120 clinical sites activated across 27 countries including the US. Patient enrolment has reached 38% of the target, keeping key milestones on track.

Southern Cross Electrical Engineering Limited has landed $90 million in new contracts spanning data centre expansion and rail infrastructure projects in Sydney, reinforcing its multidisciplinary strengths.

Acusensus Limited has announced a $30 million equity placement to bolster its balance sheet, alongside winning a landmark $34 million contract in Connecticut, marking a significant step in its US expansion. The company also reported multiple contract expansions in Australia and a new debt facility to support its growth ambitions.

Acusensus Limited has successfully raised $30 million through a placement of 20 million shares at $1.50 each, supported by both existing and new investors. The capital injection aims to fuel business development, product innovation, and operational expansion.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Cynata Therapeutics has finalised patient enrolment in its pivotal Phase 2 trial of CYP-001 for acute graft versus host disease, setting the stage for critical data due mid-2026.